TY - JOUR
T1 - Prevalence of Subclinical Cardiovascular Disease in Patients with Non-Alcoholic-Fatty Liver Disease
T2 - Analysis of the Paracelsus 10.000 Cohort Study
AU - Koutny, Florian
AU - Aigner, Elmar
AU - Datz, Christian
AU - Gensluckner, Sophie
AU - Maieron, Andreas
AU - Mega, Andrea
AU - Iglseder, Bernhard
AU - Langthaler, Patrick
AU - Frey, Vanessa
AU - Paulweber, Bernhard
AU - Trinka, Eugen
AU - Wernly, Bernhard
N1 - Lehr-KH Oberndorf und Bozen;
Aigner, Gensluckner, Paulweber: First Department ofMedicine, University Clinic Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Iglseder: Department of Geriatric
Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria; Langthaler, Frey, Trinka: Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Centre for Cognitive Neuroscience, Salzburg, Austria;Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Centre for Cognitive Neuroscience, Salzburg, Austria; Langthaler: Team Biostatistics and Big Medical Data, Paracelsus Medical University Salzburg, Salzburg, Austria; Frey, Trinka: Spinal Cord
Injury and Tissue Regeneration Center, PMU, Salzburg, Austria; Frey: Neuroscience Institute, Christian Doppler University Hospital, Paracelsus Medical University and Centre for Cognitive Neuroscience, Salzburg, Austria; Wernly: Center for Public Health and Healthcare Research,
Paracelsus Medical University of Salzburg, Salzburg, Austria
PY - 2023/9/7
Y1 - 2023/9/7
N2 - BACKGROUND: In patients with non-alcoholic fatty liver disease (NAFLD) cardiovascular diseases are more often the cause of death than the liver disease itself. However, the prevalence of atherosclerotic manifestations in individuals with NAFLD is still uncertain. This study aimed to explore the association between NAFLD and coronary artery calcification (CAC) in a Central European population.METHODS: A total of 1,743 participants from the Paracelsus 10,000 study were included. The participants underwent CAC scoring and were assessed for fatty liver index (FLI), fibrosing non-alcoholic steatohepatitis Index (FNI) and fibrosis-4 index (FIB-4 score), which are indicators for steatosis and fibrosis. Multivariable logistic regression models were calculated.RESULTS: Results revealed an association between liver steatosis/fibrosis and CAC. A FLI > 60 was associated with higher odds of NAFLD (OR 3.38, 95% CI: 2.61-4.39, p < 0.01) and increased prevalence of CAC-Score >300 compared to FLI <30 (9% vs. 3%, p < 0.01), even after adjusting for traditional cardiometabolic risk factors. While the crude odds ratios of the FIB-4 scores ≥ 1.3 and FNI score were significantly associated with increased odds of CAC, they became non-significant after adjusting for age, sex, and MetS.CONCLUSION: This study reveals a significant association between NAFLD and CAC. The findings suggest that assessing liver fat and fibrosis could enhance assessment of cardiovascular risk, but further research is needed to determine whether hepatic fat plays an independent role in the development of atherosclerosis and whether targeting liver steatosis can mitigate vascular risk.
AB - BACKGROUND: In patients with non-alcoholic fatty liver disease (NAFLD) cardiovascular diseases are more often the cause of death than the liver disease itself. However, the prevalence of atherosclerotic manifestations in individuals with NAFLD is still uncertain. This study aimed to explore the association between NAFLD and coronary artery calcification (CAC) in a Central European population.METHODS: A total of 1,743 participants from the Paracelsus 10,000 study were included. The participants underwent CAC scoring and were assessed for fatty liver index (FLI), fibrosing non-alcoholic steatohepatitis Index (FNI) and fibrosis-4 index (FIB-4 score), which are indicators for steatosis and fibrosis. Multivariable logistic regression models were calculated.RESULTS: Results revealed an association between liver steatosis/fibrosis and CAC. A FLI > 60 was associated with higher odds of NAFLD (OR 3.38, 95% CI: 2.61-4.39, p < 0.01) and increased prevalence of CAC-Score >300 compared to FLI <30 (9% vs. 3%, p < 0.01), even after adjusting for traditional cardiometabolic risk factors. While the crude odds ratios of the FIB-4 scores ≥ 1.3 and FNI score were significantly associated with increased odds of CAC, they became non-significant after adjusting for age, sex, and MetS.CONCLUSION: This study reveals a significant association between NAFLD and CAC. The findings suggest that assessing liver fat and fibrosis could enhance assessment of cardiovascular risk, but further research is needed to determine whether hepatic fat plays an independent role in the development of atherosclerosis and whether targeting liver steatosis can mitigate vascular risk.
U2 - 10.1159/000533909
DO - 10.1159/000533909
M3 - Original Article
C2 - 37678174
SN - 1011-7571
VL - 32
SP - 272
EP - 280
JO - MEDICAL PRINCIPLES AND PRACTICE
JF - MEDICAL PRINCIPLES AND PRACTICE
IS - 4-5
ER -